Otsuka plans entree into MRI with high-field unit, low-field price

Article

Another Japanese vendor is targeting the U.S. for sales of high-quality,low-cost MRI systems, but this time with a twist: the MRI technologyand manufacturing base is American. Otsuka Electronics (USA) of Fort Collins, CO, will apply forFood and Drug

Another Japanese vendor is targeting the U.S. for sales of high-quality,low-cost MRI systems, but this time with a twist: the MRI technologyand manufacturing base is American.

Otsuka Electronics (USA) of Fort Collins, CO, will apply forFood and Drug Administration approval of a 1.5-tesla imager thisyear, said president Tim O'Sullivan. The system will use a SunMicrosystems computer platform and will be priced to compete head-onwith low- and mid-field MRI systems, he said.

The U.S. company will be supported in its MRI launch withfunds from its parent, Otsuka Pharmaceutical, a Japanese giantwith $5 billion in annual sales. Otsuka's MR technology will derivelargely from the firm's U.S. MR businesses, however, O'Sullivansaid.

Otsuka purchased Phospho-Energetics, a Pennsylvania small-borespectrometer firm three years ago (SCAN 5/25/88). This businesswas moved to Colorado and merged with Chemagnetics, Otsuka's MRsolids spectroscopy subsidiary, last year (SCAN 8/15/90). O'Sullivanwas hired away from Philips Medical Systems at that time to headup the unified Otsuka MR business. He had served as vice presidentof CT and MRI marketing at Philips.

Otsuka also owns a 20% interest in Magnex of Great Britainand Japan Magnet Technologies, a Japanese joint venture formedtwo years ago by Otsuka, Magnex and Kobe Steel. Kobe holds a controllinginterest in JMT (SCAN 10/11/89).

Although the 1.5-tesla MRI prototype is not quite complete,Otsuka has started to build its MRI sales force. John Ariatti,former MRI director of marketing for Toshiba America Medical Systems,has been hired as western regional sales manger.

Ariatti joins Len Platt, regional manager for the Southeast,and Larry Hanson in the Midwest, said Dale Grant, vice presidentof sales & marketing. All three regional sales managers werehired this month.

Otsuka is negotiating with two potential clinical sites tohouse the first 1.5-tesla installations, Grant said. The firmplans to show the unit as a works-in-progress at the RadiologicalSociety of North America conference in Chicago this December.

The systems should be well suited to satisfy the two majordemand trends in the U.S. MRI market, O'Sullivan said.

"There is a significant market need for low-cost systems,but also a general consensus among neurological specialists that1.5-tesla (field strength) is better. We know we can provide a1.5-tesla system at around the same price as the lower performanceunits," he told SCAN. The Otsuka MRI system should sell inthe area of $1.25 million, he said.

Since most of Otsuka's MR technology originated in the U.S.,the firm's growth in this market should follow a different coursethan other Japanese vendors. Toshiba, Shimadzu and Hitachi, forinstance, all started with imported MRI systems from Japan. Otsuka'ssystem, on the other hand, will be manufactured in the U.S. andmay actually be exported to Japan in the future.

"This is an American company with American managementthat knows the medical business," O'Sullivan said.

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.